Skip to main content

Table 2 Parasitological and clinical outcomes among patients treated with artesunate + sulfadoxine-pyrimethamine and artemether-lumefantrine after 28 days of follow-up, Yemen (2010–2013)

From: High efficacy of two artemisinin-based combinations: artesunate + sulfadoxine-pyrimethamine and artemether-lumefantrine for falciparum malaria in Yemen

Drug Site Year n PD3+ Without PCR-correction With PCR-correction
Excluded/loss LCF LPF ACPR Cure rate (KM) Excluded/loss LCF LPF ACPR Cure rate (KM)
n (%) n (%) n (%) n (%) n (%) % (95 % CI) n (%) n (%) n (%) n (%) (%) (95 % CI)
AS + SP Al-Udayn 2010 85 0 (0) 2 (2.4) 0 (0) 0 (0) 83 (100) 100 (95.7–100) 2 (2.4) 0 (0) 0 (0) 83 (100) 100 (95.7–100)
AS + SP Sharas 2010 93 0 (0) 11 (11.8) 0 (0) 0 (0) 82 (100) 100 (95.6–100) 11 (11.8) 0 (0) 0 (0) 82 (100) 100 (95.6–100)
AS + SP Tur Bani Qa’is 2010 95 0 (0) 12 (13.7) 1 (1.2) 1(1.2) 81 (97.6) 97.6 (91.8–99.4) 14(14.7) 0 (0) 0 (0) 81 (100) 100 (95.9–100)
AS + SP Al-Qaflah 2011 90 0 (0) 6 (6.7) 0 (0) 0 (0) 84 (100) 100 (95.7–100) 6 (6.7) 0 (0) 0 (0) 84 (100) 100 (95.7–100)
AS + SP Bajil 2013 102 0 (0) 3 (2.9) 1 (1) 2 (2) 96 (97) 96 (89.6–98.5) 4 (3.9) 2 (2) 0 (0) 96 (98) 98 (92.2–99.5)
AL Bajil 2009 80 0 (0) 6 (7.5) 0 (0) 0 (0) 74 (100) 100 (95.1–100) 6 (7.5) 0 (0) 0 (0) 74 (100) 100 (95.1–100)
AL Jabal-Al-Sharq 2010 95 1 (1.1) 5 (5.3) 0 (0) 2 (2.2) 88 (97.8) 97.8 (92.2–99.7) 7 (7.4) 0 (0) 0 (0) 88 (100) 100 (95.9–100)
AL Tur Bani Qa’is 2013 93 0 (0) 5 (5.4) 5 (5.7) 0 (0) 83 (94.3) 94.3 (87.2–98.1) 10 (10.8) 0 (0) 0 (0) 83 (100) 100 (95.7–100)
  1. LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response, KM Kaplan–Meier, CI confidence interval, PD3+ positive blood film on day 3